RNA Therapeutics: the Next Generation of Drugs for Cardiovascular Diseases.
Curr Atheroscler Rep
; 24(5): 307-321, 2022 05.
Article
in English
| MEDLINE | ID: covidwho-1850420
ABSTRACT
PURPOSE OF REVIEW RNA therapeutics are a new and rapidly expanding class of drugs to prevent or treat a wide spectrum of diseases. We discuss the defining characteristics of the diverse family of molecules under the RNA therapeutics umbrella. RECENT FINDINGS:
RNA therapeutics are designed to regulate gene expression in a transient manner. For example, depending upon the strategy employed, RNA therapies offer the versatility to replace, supplement, correct, suppress, or eliminate the expression of a targeted gene. RNA therapies include antisense nucleotides, microRNAs and small interfering RNAs, RNA aptamers, and messenger RNAs. Further, we discuss the mechanism(s) by which different RNA therapies either reduce or increase the expression of their targets. We review the RNA therapeutics approved (and those in trials) to treat cardiovascular indications. RNA-based therapeutics are a new, rapidly growing class of drugs that will offer new alternatives for an increasing array of cardiovascular conditions.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Cardiovascular Diseases
/
MicroRNAs
/
Aptamers, Nucleotide
Limits:
Humans
Language:
English
Journal:
Curr Atheroscler Rep
Journal subject:
Vascular Diseases
Year:
2022
Document Type:
Article
Affiliation country:
S11883-022-01007-9
Similar
MEDLINE
...
LILACS
LIS